NCPA - National Center for Policy Analysis

Pharmaceutical Marketing, the FDA and Free Speech

January 5, 2016

The U.S. Justice Department and state attorneys general have repeatedly used the threat of prosecutions for drugmakers touting off-label uses of pharmaceuticals to wring billions of dollars in settlements, fines and civil damages from them. But now drugmakers are seizing on a Second Circuit court decision to block future extractions, writes NCPA Senior Fellow Thomas Hemphill.


Browse more articles on Health Issues